Source: Annual Congress 2005 - Pathogenesis of OSA
Disease area: Sleep and breathing disorders



Rating:

Share or cite this content

Citations should be made in the following way:
C. B. Bucca, L. Brussino, E. Panaro, P. Bigo, L. Mangiardi, A. Cicolin (Turin, Italy). ACE-inhibitors and obstructive sleep apnoea. Eur Respir J 2005; 26: Suppl. 49, 2325

Member's Comments

No comment yet.

Related content which might interest you: Hypertension and obstructive sleep apnoea Source: Annual Congress 2006 - Obstructive sleep apnoea and cardiovascular diseases Year: 2006 Non-CPAP therapies in obstructive sleep apnoea Source: Guideline 2011 Year: 2011 Ato-oxy as the first successful pharmacotherapy for obstructive sleep apnoea Source: International Congress 2019 – New horizons for pharmacotherapy of sleep-disordered breathing: from bench to bedside Year: 2019 The velumount device for obstructive sleep apnoea Source: Annual Congress 2009 - Assessment and therapeutical interventions in obstructive sleep apnoea Year: 2009 Comorbidities of obstructive sleep apnoea syndrome Source: Annual Congress 2011 - Comorbid obstructive sleep apnoea (OSA) and OSA comorbidities Year: 2011 Albuminuria in children with obstructive sleep apnea Source: Annual Congress 2011 - Obstructive sleep apnoea: inflammation and metabolism Year: 2011 Leptin in obstructive sleep apnea Source: Eur Respir J 2001; 18: Suppl. 33, 333s Year: 2001 Should caffeine be avoided in obstructive sleep apnea? Source: Annual Congress 2009 - Assessment and therapeutical interventions in obstructive sleep apnoea Year: 2009 Metabolic syndrome in obstructive sleep apnoea patients Source: Annual Congress 2007 - Sleep apnoea Year: 2007 Can leptin be used to treat obstructive sleep apnoea? Source: International Congress 2019 – New horizons for pharmacotherapy of sleep-disordered breathing: from bench to bedside Year: 2019 Pathophysiological consequences of obstructive sleep apnoea Source: Annual Congress 2006 - Obstructive sleep apnoea and cardiovascular diseases Year: 2006 Change in PLMS after treatment of obstructive sleep apnea Source: Eur Respir J 2007; 30: Suppl. 51, 593s Year: 2007 NT-proBNP in obstructive sleep apnoea (OSA) Source: Eur Respir J 2006; 28: Suppl. 50, 415s Year: 2006 Predictors of hypercapnia in obstructive sleep apnoea (OSA) Source: Annual Congress 2010 - Lung disease and mountain sickness: the importance of ventilatory control Year: 2010 Unrecognised systemic hypertension in patients with obstructive sleep apnoea Source: Eur Respir J 2006; 28: Suppl. 50, 643s Year: 2006 Awakening headaches are associated with obstructive sleep apnea Source: Eur Respir J 2002; 20: Suppl. 38, 452s Year: 2002 Acetazolamide improves central sleep apnea in patients with obstructive sleep apnea syndrome at altitude Source: Annual Congress 2009 - Assessment and therapeutical interventions in obstructive sleep apnoea Year: 2009 Vasoconstriction during the night in patients with obstructive sleep apnea syndrome Source: Eur Respir J 2006; 28: Suppl. 50, 419s Year: 2006 Unrecognised hypertension in patients screened for obstructive sleep apnoea Source: Eur Respir J 2005; 26: Suppl. 49, 40s Year: 2005 Should mixed apnea be classified with obstructive sleep apnea? Source: Annual Congress 2009 - Assessment and therapeutical interventions in obstructive sleep apnoea Year: 2009